Overview

Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta

Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SION-719 when given to people with CF who are already taking Trikafta.
Phase:
PHASE2
Details
Lead Sponsor:
Sionna Therapeutics Inc.